【摘要】 目的探讨血小板源性生长因子C(PDGF-C)在晚期非小细胞肺癌中的表达及临床意义。方法采用免疫组织化学方法对170例经病理证实的初治晚期NSCLC标本进行分析,检测PDGF-C的表达水平,并给予患者重组人血管内皮抑素(恩度)联合化疗。观察化疗有效率、疾病控制率、1年生存率及2年生存率。结果腺癌患者恩度联合化疗有效率为60.0%,疾病控制率为80.9%,其中PDGF-C表达阳性的腺癌患者恩度联合化疗有效率为59.2%(45/76),疾病控制率为81.6%(62/76),1年生存率和2年的生存率分别为68.4%和27.6%。PDGF-C表达阴性的腺癌患者1年生存率和2年的生存率分别为66.7%和28.2%。结论 PDGF-C在肺腺癌中的表达阳性率较高,PDGF-C表达阳性的乳头型或腺泡为主型的腺癌患者恩度联合化疗有效率虽未能提高,但是这类患者1、2年的生存率明显提高,预后较好。更多还原

【Abstract】 Objective To explore the expression and the clinical significance of platelet derived growth factor-C( PDGF-C) in the treatment of advanced adenocarcinoma of lung. Methods The samples of 170 patients diagnosed with advanced NSCLC were analyzed by immunohistochemistry and the level of PDGF-C was determined. The patients were treated with recombinant human endostatin and chemotherapy. The efficacy of chemotherapy,diseases control rate,1-year-survival and 2-yearsurvival rates were observed. Results The efficacy rate of recombinant human endostatin and chemotherapy was 60. 0% and diseases control rate was 80. 9%. The effective rate of recombinant human endostatin and chemotherapy in the patients with positive PDGF-C expression was 59. 2%( 45 /76),and diseases control rate was 81. 6%( 62 /76),1-year-survival and 2-year-survival rates were 68. 4% and27. 6%,respectively. The 1-year-survival and 2-year-survival rates were 66. 7% and 28. 2% in patients with negative PDGF-C expression. Conclusion The positive rate of PDGF-C in adenocarcinoma patients is higher. Although the efficacy of in papillary adenocarcinoma and alveolus adenocarcinoma patients with recombinant human endostatin and chemotherapy shows no obvious improvement,theses patients have better 1-year-survival and 2-year-survival rates and prognosis.更多还原